COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #131 of 230
9/12 Late treatment study
Heberto et al., IJC Heart & Vasculature, doi:10.1016/j.ijcha.2020.100638 (Peer Reviewed)
Implications of myocardial injury in Mexican hospitalized patients with coronavirus disease 2019 (COVID-19)
Source   PDF   Share   Tweet
Observational prospective 254 hospitalized patients, HCQ+AZ mortality odds ratio OR 0.36, p = 0.04.
Ventilation OR 0.20, p = 0.008.

Heberto et al., 9/12/2020, prospective, Mexico, North America, peer-reviewed, 8 authors.
risk of death, 53.6% lower, RR 0.46, p = 0.04, treatment 139, control 115, odds ratio converted to relative risk.
risk of ventilation, 65.6% lower, RR 0.34, p = 0.008, odds ratio converted to relative risk.
Details of all 230 studies    Meta analysis
Please submit corrections, updates, or comments.
Submit